与化疗相比,一种新的药物组合大大扩大了先进的膀胱癌患者的生存范围。 A new drug combo significantly extends survival for advanced bladder cancer patients compared to chemotherapy.

第3阶段试验发现,Loqtorzi结合了disitamab vedotin和toripalimab, 与标准的化疗相比,大大改善了HER2-表现为先进或转移性泌尿道癌的病人的存活率。 A phase 3 trial found that Loqtorzi, a combination of disitamab vedotin and toripalimab, significantly improves survival for patients with HER2-expressing advanced or metastatic urothelial cancer compared to standard chemotherapy. 在18.2个月之后,混合组的中位无进展性存活率为13.1个月,而中位无进展性存活率为6.5个月,中位总体存活率为31.5个月,而中位总体存活率为16.9个月,其累进或死亡风险降低64%,死亡风险降低46%。 After 18.2 months, the combination group had a median progression-free survival of 13.1 months versus 6.5 months and a median overall survival of 31.5 months versus 16.9 months, with a 64% lower risk of progression or death and a 46% lower risk of death. 反应率较高,反应率随结合而延长,需要晚些治疗的病人较少。 Response rates were higher and responses lasted longer with the combination, and fewer patients needed later treatments. 在新的疗法中,严重的副作用不那么常见。 Serious side effects were less common with the new regimen. 在2025年ESMO大会上提出并在《新英格兰医学杂志》上公布的结果表明,它可能成为新的第一线护理标准。 Results presented at the 2025 ESMO Congress and published in the New England Journal of Medicine suggest it may become the new first-line standard of care.